Sema4 Holdings Corp.
SMFRW
NASDAQ Global Select0.02
USD
- -
- -
Sema4 Holdings Corp.
SMFRW
(NASDAQ Global Select)
Recent
price
0.02
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Sema4 Holdings Corp. (SMFRW), formerly operating as a health information company focused on genomic testing and AI-driven diagnostics, now functions primarily through its warrants tied to GeneDx Holdings Corp., following a corporate restructuring and name change in January 2023. The company offers warrants exercisable into shares of GeneDx Holdings Corp., which provides exome and genome testing for pediatric and rare disease diagnostics; Centrellis, an AI-powered health intelligence platform delivering insights for biopharma drug discovery, clinical trials, and sequencing services; Sema4 Signal for precision oncology care; carrier screening, noninvasive prenatal testing, newborn screening, and hereditary cancer testing; and previously COVID-19 testing solutions. GeneDx Holdings Corp., its successor entity trading as WGS, maintains these core genomic and clinical data offerings, headquartered in Stamford, Connecticut since its 2020 founding via a business combination. Recent major developments include the April 2022 acquisition of GeneDx from OPKO Health for $150 million cash plus 80 million shares and up to $150 million in milestones, a $200 million private placement led by investors including Pfizer, a strategic pivot to rare disease diagnostics with exit from reproductive health, and the January 2023 name change to GeneDx Holdings Corp. with ticker shift to WGS; SMFRW warrants remain outstanding with expiration in July 2026. The company targets healthcare providers, biopharma, and patients globally, primarily in the United States, emphasizing precision medicine through integrated genomic and clinical data analysis.